All In MedTech

Device Trial Radar · NCT06294795

Toric Intraocular Lens Implantation in Pediatric Cataract

A Prospective Randomized Controlled Trial of Toric Intraocular Lens Implantation in Pediatric Cataractous Eyes

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Mar 1, 2024

Primary completion

Feb 5, 2025

Study completion Mar 16, 2026

Sponsor

Lead sponsor
Kazakh Eye Research InstituteResearch network
Sponsor type
Research network
First posted
Mar 6, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the visual and refractive outcomes after an intraocular lens (IOL) implantation in pediatric eyes with cataract and preexisting corneal astigmatism

Conditions

  • Cataract Congenital
  • Astigmatism
  • IOL

Interventions

  • congenital/pediatric cataract surgeryProcedure

    All procedures are performed under general anesthesia according to the standard technique of congenital/pediatric cataract surgery with an intraocular lens (IOL) implantation. Paracentesis is performed at 2.30 o\'clock using a 20-gauge straight microvitreoretinal (MVR) knife; a high molecular weight ophthalmic viscosurgical devices (OVD) is injected into the anterior chamber. Then a 2.4 mm corneal tunnel incision is made at 11 o'clock with a disposable keratome knife 2.2 mm. Circular continuous capsulorhexis (≈ 5.5 mm). Сortical cleaving hydrodissection is followed by bimanual phacoaspiration in irrigation-aspiration mode. OVD is injected in the anterior chamber and an IOL is implanted in the capsular bag. Residual OVD is aspirated from the anterior chamber and behind the IOL and followed by IOL alignment. The surgery is completed with corneal hydration at the tunnel incision site.

  • Non-Toric IOLsDevice

    A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF for the non-toric group (Alcon Laboratories, Inc.) ARE implanted.

  • Toric IOLsDevice

    A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx for the toric group (Alcon Laboratories, Inc.) were implanted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uncorrected (UCDVA) and corrected (CDVA) distance visual acuityTime frame: recorded at each follow-up (on the fifth day, first month, third month, sixth month, and first year)
  2. Uncorrected (UCNVA) and corrected (CNVA) near visual acuityTime frame: recorded at each follow-up (on the fifth day, first month, third month, sixth month, and first year)
  3. Refraction measurementsTime frame: recorded at each follow-up (on the fifth day, first month, third month, sixth month, and first year)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kazakh Eye Research Institute

    Almaty, Kazakhstan

  • Kazakh Eye Research Institute

    Astana, Kazakhstan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.